La comunità scientifica italiana (area life sciences) e la sfida dei progetti comunitari.

Slides:



Advertisements
Similar presentations
RICERCA E INNOVAZIONE QUALITA E SVILUPPO Presentazione di Umberto Bertazzoni Siena, 12 dicembre 2005.
Advertisements

Mental health strategy of the Medical Research Council (UK) Opportunities for European engagement and a role of FEAM European Parliament 22 nd March 2011.
Story of an Essential Resolution The WHO Resolution on A Global Framework on Essential Health R&D.
5 Framework Programme ( ) Information Society Technologies Key Action 1: Systems and Services for the Citizen 5 th Framework Programme (1998.
Life Science Cluster in Krakow
Slide 1 Research in support to Human Biomonitoring E&H, Consultative Forum Meeting 19 October 2005 Luxembourg P. Valette DG Research, Directorate Environment.
February 2006 WHO's Contribution to Scaling Up towards Universal Access to HIV/AIDS Prevention, Care and Treatment Department of HIV/AIDS.
Personalized Medicine in California Kathryn Lowell, Deputy Secretary for Life Sciences and Health Systems February, 2009.
Science, research and developmentEuropean Commission LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH Applications of knowledge and technologies in.
Version 5, Revised on ERPA 2014 © 20. ERPA Project – Horizon 2020  Horizon 2020 = the new EU programe for Research & Innovation  Started 01/01/2014.
1 Stéphane Hogan Head of Coordination Unit Directorate Health DG Research – European Commission Launching FP7 – Riga, 5 February 2007 The Health theme.
Indridi Benediktsson June 2007 International Collaboration in FP7 Health Research Dr. Indridi Benediktsson Directorate Health Horizontal Aspects and Coordination.
European Framework Programme for Business FP7 UK Technology Strategy Board Driving Innovation FP7UK Opportunities in FP 7 The Health research theme Biomed.
EU support for Health Research: from FP6 to FP7
EU RTD + FP Cancer Treatment: A priority for patients in Europe 7 th European Health Forum Bad Gastein 7 October, 2004 Cornelius Schmaltz MD European.
Combating major diseases Gender aspects in research Gender aspects in research have a particular relevance to this theme as risk factors, biological mechanisms,
1 Biomedical Sciences Public and Environmental Health Regenerative Medicine Translational Research.
International Collaboration in FP7 Health Research
21 October 2005 CNRS Building the Europe of Knowledge Octavi Quintana Trias, Director, European Commission Health Research Directorate, DG Research, Health.
1 SIMG Florence ppt The Horizons of Predictive Medicine Dr Ian Gilham Worldwide Director, Predictive Medicine Glaxo Wellcome Research and Development.
Challenges in Clinical Applications for Nanotechnology N. Tony Eissa, MD Table 3.
What Do Toxicologists Do?
EoI assesment and presentation NCP 24 October 2002 Confronting the major communicable diseases linked to poverty Health Directorate F3 unit: Poverty related.
Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"
Title of Presentation 1 EU-ASEAN S&T cooperation to jointly tackle societal challenges Opportunities for future EU-ASEAN collaborations.
Emerging infections and Health Protection In Scotland Looking to the future Kirsty Roy and Martin Donaghy Health Protection Scotland Scottish Government.
European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 Towards the Sixth Framework Programme Parallel Forum V 26 September 2002 Public.
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
SMEsgoHealth&Match2BioSME International Training&Workshop - September 13, 2007, Riga Health Theme in FP7 Dr. Uldis Berkis NCP Latvia Research areas in.
FP7 Health Work Programme MALTA 25 September 2008 Joana Namorado Horizontal Aspects & Coordination Directorate Health - Ethics/Gender DG Research – European.
Horizon 2020 The EU Framework Programme for Research and Innovation Health, Demographic Change and Wellbeing Lul Raka, NCP for Horizon 2020 – Health.
Director, DG RTD, Directorate International Cooperation
The Sixth RTD Framework Programme Thematic Priority 1 Life Sciences: Genomics & Biotechnology for Health
1 Charles Kessler European Commission Brussels FP7 2 nd call – April 2007 Health research in FP7 Innovative technologies for medicine Bialystok, 29 May.
Recognition Of Team Science Faculty Appointments, Promotions and Titles at The Geisel School of Medicine at Dartmouth “Recognition by peers as an investigator.
Where to focus? Horizon 2020 'Health, demographic change and wellbeing' Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels,
The Innovative Medicines Initiative (IMI) High level the IMI Concept, Strategic Research Agenda and Call topics Eva Lindgren.
Integrated Biomedical Information for Better Health Workprogramme Call 4 IST Conference- Networking Session.
1 EU-funded health research activities against TB: FP6 actions and perspectives toward FP7 DG Research - European Commission 22 MARCH 2007.
Svetlana Spassova, MD Ministry of Health, Bulgaria Chisinau
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD: a public health approach to innovation Hans V. Hogerzeil Director, Medicines Policy and Standards WHO, Geneva.
Clinical trials in Framework programme 7 (FP7) EU Judita Kinkorová 2. Národní konference o doporučených postupech, Olomouc 13. listopadu 2010.
Seventh Framework Programme Theme 1 - Health Ph D.Olguta Iordache Health - NCP.
Samudrala group - overall research areas CASP6 prediction for T Å C α RMSD for all 70 residues CASP6 prediction for T Å C α RMSD for all.
Horizon 2020 First reflections Tallinn
XVII INTERNATIONAL AIDS CONFERENCE PANCAP Satellite Meeting Hon Douglas Slater, Minister of Health, St. Vincent and the Grenadines.
Presentation/Phenotype
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
HORIZON 2020 SC1-Health, demographic change and wellbeing challenge Марина Николовска Министерство за образование и наука
The Medical Research Council Presentation to the Portfolio Committee on Science and Technology March 16, 2005
Joe Pekny, Professor Chemical Engineering Director, e-Enterprise Center Discovery Park Marietta Harrison, Professor Medicinal Chemistry & Molecular Pharmacology.
EHFG 7 October 2005 – Patient Safety & Research UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European.
GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.
Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.
National Information Day Greece 23 July 2015 Funding priorities under the work plan 2015.
RESEARCH FOR HEALTH RESEARCH AGENDA Gilbert Kokwaro, PhD Consortium for National Health Research.
1 Modelling and Simulation EMBL – Beyond Molecular Biology Physics Computational Biology Chemistry Medicine.
Richard Escritt, Director – Coordination of Community Actions DG Research, European Commission “The development of the ERA: Experiences from FP6 and reflections.
PRESENTAZIONE DEL WORK PROGRAMME 2013 HEALTH Gabriella Balestra BIOLAB - Dipartimento di Elettronica e Telecomunicazioni.
Medical and Health research in Norway – in brief Director Mari K. Nes 22 June 2006.
I farmaci innovativi in una prospettiva europea Giuseppe M.C. Rosano, MD, PhD Cardiovascular and Cell Sciences Research Institute, St George's University.
TITIN ANDRI WIHASTUTI SCHOOL OF NURSING FACULTY OF MEDICINE
The Medical Research Council
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
EU funding opportunities
Work Programme The social challenge “Health, Demographic Change and Wellbeing” Maia Okujava NCP for Health, Demographic Change and weii-being,
Call topic identification for 2019 call
7th EU Research FP has ten themes defined in order:
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
M-H Pinard-van der Laan
Presentation transcript:

La comunità scientifica italiana (area life sciences) e la sfida dei progetti comunitari

applications DEUKITFRNLESSEBEDKPLFiATGRHUCZPTIEEESISKLTCYLVLuMT

percentuale di successo 0,00% 5,00% 10,00% 15,00% 20,00% 25,00% 30,00% 35,00% 40,00% EUBEFRUKIENLDEATDKITSEESFiPTHUEEGRCZLTCYSIPLLuSKLVMT

0% 5% 10% 15% 20% 25% 30% 35% 40% 45% UNIRECSMEINDOTHER percentuale di partecipazione di ricercatori italiani

percentuale di partecipazione 0% 10% 20% 30% 40% 50% 60% 70% UNIRECSMEINDOTHER percentuale di successo 0,00% 5,00% 10,00% 15,00% 20,00% 25,00% 30,00% 35,00% 40,00% AllUNIRECSMEsIND Other IT FR

-1,000 -0,800 -0,600 -0,400 -0,200 0,000 0, Aree disciplinari Specializzazione scientifica Italiana - Pubblicazioni Symmetric Relative Specialization Index (RSI) Gastroenterology and Hepatology Hematology Oncogenesis & Cancer Research Oncology Pharmacology/Toxicology Space Science Instrumentation/Measurement Physics Inorganic&Nuclear Chemistry

a) incrementare i finanziamenti; b) eliminare lobbligo di creare networks di ricerca per accedere ai finanziamenti a meno che non esistano delle reali esigenze di collaborazione; c) offrire spazi significativi al finanziamento di nuovi gruppi di ricerca; d) riservare una quota significativa delle risorse al finanziamento di progetti di ricerca liberi, cioè non finalizzati al raggiungimento di obiettivi preordinati; e) dare spazio alla mobilità dei ricercatori, non limitandola alle attività di formazione. i) uniformità delle politiche di finanziamento pubblico; ii) coordinamento delle politiche di finanziamento nazionali e europee; iii) incentivi alla mobilità transnazionale dei group leaders; iv) accesso a tutti i ricercatori europei alle fonti di finanziamento delle singole nazioni.

Collaborative research will constitute the bulk and the core of EU research funding Joint Technology Initiatives will mainly be created on the basis of the work undertaken by the European Technology Platforms - Emphasis on research themes rather than on instruments - Significant simplification of its operation - Focus on developing research that meets the needs of European industry, through the work of Technology Platforms and the new Joint Technology Initiatives - Establishment of a European Research Council, funding the best of European science - Integration of International cooperation in all four programmes - Development of Regions of Knowledge - A Risk-Sharing Finance Facility aimed at fostering private investment in research Lower number of partners in consortia and a greater focus on smaller projects

Biotechnology, generic tools and technologies for human health This activity aims at developing and validating the necessary tools and technologies that will make possible the production of new knowledge and its translation into practical applications in the area of health and medicine. –High-throughput research The focus will be on new technologies for: sequencing; gene expression, genotyping and phenotyping; structural genomics; bioinformatics and systems biology; other omics. –Detection, diagnosis and monitoring: The focus will be on a multidisciplinary approach integrating areas such as: molecular and cellular biology, physiology, genetics, physics, chemistry, nanotechnologies, microsystems, devices and information technologies. Non- or minimally- invasive and quantitative methods and quality assurance aspects will be emphasised. –Innovative therapeutic approaches and interventions: The focus will be on gene and cell therapy, regenerative medicine, transplantation, immunotherapy and vaccines, and other medicines. Related technologies, such as advanced targeted delivery systems, advanced implants and prosthetics, and non- or minimally-invasive technology-assisted interventions will also be addressed. –Predicting suitability, safety and efficacy of therapies The focus will be on approaches such as pharmacogenomics, in silico, in vitro (including alternatives to animal testing) and in vivo methods and models. Proposal for a COUNCIL DECISION concerning the Specific Programme Cooperation implementing the Seventh Framework Programme ( ) of the European Community for research, technological development and demonstration activities

Translating research for human health This activity aims at increasing knowledge of biological processes and mechanisms involved in normal health and in specific disease situations, to transpose this knowledge into clinical applications, and to ensure that clinical data guide further research. – Integrating biological data and processes: large-scale data gathering, systems biology. Large scale data gathering: The focus will be on: genomics; proteomics; population genetics; comparative and functional genomics. - Systems biology: the focus will be on multidisciplinary research that will integrate a wide variety of biological data and will develop and apply system approaches to understand and model biological processes. – Research on the brain and related diseases, human development and ageing. Brain and brain-related diseases The focus will be to explore brain functions, from molecules to cognition, and to address neurological and psychiatric diseases and disorders, including regenerative and restorative therapeutic approaches. Human development and ageing: The focus will be on the study of human and model systems, including interactions with factors such as environment, behaviour and gender. – Translational research in major infectious diseases: to confront major threats to public health. Anti-microbial drug resistance: the focus will be on combining basic research on molecular mechanisms of resistance, microbial ecology and host-pathogen interactions with clinical research towards new interventions to reduce the emergence and spread of multi-drug resistant infections. HIV/AIDS, malaria and tuberculosis: the focus will be on developing new therapies, diagnostic tools, preventive vaccines and chemical transmission barriers such as HIV microbicides Emerging epidemics: the focus will be on confronting emerging pathogens with pandemic potential including zoonoses (e.g. SARS and highly pathogenic influenza). – Translational research in other major diseases. Cancer Cardiovascular disease Diabetes and obesity Rare diseases Other chronic diseases

Optimising the delivery of health care to European citizens This activity aims at providing the necessary basis both for informed policy decisions on health systems and for more effective strategies of health promotion, disease prevention, diagnosis and therapy. – Enhanced health promotion and disease prevention: – Translating clinical research into clinical practice – Quality, solidarity and sustainability of health systems